{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:14:03Z","timestamp":1787242443527,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA168762"],"award-info":[{"award-number":["CA168762"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA186781"],"award-info":[{"award-number":["CA186781"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA107476"],"award-info":[{"award-number":["CA107476"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA 248398"],"award-info":[{"award-number":["CA 248398"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA 240139"],"award-info":[{"award-number":["CA 240139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA 168762"],"award-info":[{"award-number":["CA 168762"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA168762"],"award-info":[{"award-number":["CA168762"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA186781"],"award-info":[{"award-number":["CA186781"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA107476"],"award-info":[{"award-number":["CA107476"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The prevalence of monoclonal gammopathy of undetermined significance (MGUS) increases with age, but the study of age of onset and the prevalence of MGUS in younger individuals has been limited by lack of sensitive serum protein testing methods. In addition, there is marked racial disparity in the prevalence in Black individuals compared with White individuals and it is important to determine if MGUS has an earlier age of onset in Black individuals. In this first large mass spectrometry-based population-based screening study of MGUS, we evaluated 12,378 individuals (3598 White, 4075 Black, 4147 Mexican Americans, and 558 others) aged 10\u201349 years of age. The study used serum samples from the National Health and Nutritional Examination Survey (NHANES) III. MGUS was identified in 177 persons (1.28%, 95% CI 0.95, 1.60). MGUS was detectable in 0.2% of individuals age 10\u201319 years and the prevalence increased with age to 0.88%, 1.46%, and 2.82% in individuals ages 20\u201329, 30\u201339, and 40\u201349, respectively. The age-adjusted prevalence of MGUS was significantly higher in Black individuals compared with White individuals, 1.49% (1.13, 1.95) versus 0.82% (0.57, 1.18),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u2009&lt;\u20090.01. MGUS had an earlier age of onset in Black individuals; the increased prevalence of MGUS among Black compared with White individuals was apparent at age 30\u201339 years, 2.94% vs 1.42%, and this disparity increased further in the age group 40\u201349 years to 5.2% vs 2.8%, respectively. There was no significant difference in the prevalence of MGUS between White individuals and Mexican American individuals in the overall cohort, or within any specific age group. The study using a highly sensitive mass spectrometry-based assay demonstrates onset of monoclonal gammopathy in the second decade of life, with a higher prevalence among the Black individuals with comparable prevalence among the White and Mexican individuals, a disparity that increases with advancing age.\n                  <\/jats:p>","DOI":"10.1038\/s41408-026-01518-7","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:06:10Z","timestamp":1779721570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10\u201349 years of age: a population-based study from the National Health and Nutritional Examination Survey"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1720-335X","authenticated-orcid":false,"given":"David","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-2124","authenticated-orcid":false,"given":"Dirk R.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"1518_CR1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJMra2412716","volume":"393","author":"SV Rajkumar","year":"2025","unstructured":"Rajkumar SV, Kumar S. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2025;393:1315\u201326. https:\/\/doi.org\/10.1056\/NEJMra2412716.","journal-title":"N Engl J Med"},{"key":"1518_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.97","volume":"7","author":"O Landgren","year":"2017","unstructured":"Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J. 2017;7:e618. https:\/\/doi.org\/10.1038\/bcj.2017.97.","journal-title":"Blood Cancer J"},{"key":"1518_CR3","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u20139. https:\/\/doi.org\/10.1056\/NEJMoa01133202.","journal-title":"N Engl J Med"},{"key":"1518_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood.2024025415","volume":"145","author":"A Visram","year":"2025","unstructured":"Visram A, Larson D, Norman A, Dispenzieri A, Murray D, Kyle R, et al. Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection. Blood. 2025;145:325\u201333. https:\/\/doi.org\/10.1182\/blood.2024025415.","journal-title":"Blood"},{"key":"1518_CR5","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","volume":"82","author":"O Landgren","year":"2007","unstructured":"Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82:1468\u201373. https:\/\/doi.org\/10.1016\/S0025-6196(11)61089-6.","journal-title":"Mayo Clin Proc"},{"key":"1518_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","volume":"114","author":"CM Vachon","year":"2009","unstructured":"Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114:785\u201390. https:\/\/doi.org\/10.1182\/blood-2008-12-192575.","journal-title":"Blood"},{"key":"1518_CR7","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412\u20137. https:\/\/doi.org\/10.1182\/blood-2008-12-194241.","journal-title":"Blood"},{"key":"1518_CR8","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.mayocp.2012.06.014","volume":"87","author":"TM Therneau","year":"2012","unstructured":"Therneau TM, Kyle RA, Melton LJ 3rd, Larson DR, Benson JT, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012;87:1071\u20139. https:\/\/doi.org\/10.1016\/j.mayocp.2012.06.014.","journal-title":"Mayo Clin Proc"},{"key":"1518_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1709974.","journal-title":"N Engl J Med"},{"key":"1518_CR10","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362\u20139. https:\/\/doi.org\/10.1056\/NEJMoa054494.","journal-title":"N Engl J Med"},{"key":"1518_CR11","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113:6386\u201391. https:\/\/doi.org\/10.1182\/blood-2009-02-203471.","journal-title":"Blood"},{"key":"1518_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","volume":"116","author":"O Landgren","year":"2010","unstructured":"Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 2010;116:1056\u20139. https:\/\/doi.org\/10.1182\/blood-2010-01-262394.","journal-title":"Blood"},{"key":"1518_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/leu.2014.34","volume":"28","author":"O Landgren","year":"2014","unstructured":"Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28:1537\u201342. https:\/\/doi.org\/10.1038\/leu.2014.34.","journal-title":"Leukemia"},{"key":"1518_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00408-4","volume":"11","author":"DL Murray","year":"2021","unstructured":"Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021;11:24. https:\/\/doi.org\/10.1038\/s41408-021-00408-4.","journal-title":"Blood Cancer J"},{"key":"1518_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0263-z","volume":"9","author":"D Murray","year":"2019","unstructured":"Murray D, Kumar SK, Kyle RA, Dispenzieri A, Dasari S, Larson DR, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019;9:102. https:\/\/doi.org\/10.1038\/s41408-019-0263-z.","journal-title":"Blood Cancer J"},{"key":"1518_CR16","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/rcm.7314","volume":"29","author":"DR Barnidge","year":"2015","unstructured":"Barnidge DR, Krick TP, Griffin TJ, Murray DL. Using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine. Rapid Commun Mass Spectrom. 2015;29:2057\u201360. https:\/\/doi.org\/10.1002\/rcm.7314.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"1518_CR17","unstructured":"Ezzati TM, Massey JT, Waksberg J, Chu A, Maurer KR. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 1992;2:1\u201335. (In eng) (http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1413563)."},{"key":"1518_CR18","unstructured":"Curtin LR, Mohadjer LK, Dohrmann SM, Montaquila JM, Kruszan-Moran D, Mirel LB, et al. The National Health and Nutrition Examination Survey: Sample Design, 1999-2006. Vital and health statistics Series 2, Data evaluation and methods research 2012:1\u201339. (http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22788053)."},{"key":"1518_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00624-6","volume":"12","author":"A Dispenzieri","year":"2022","unstructured":"Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, et al. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 \/07LT). Blood Cancer J. 2022;12:27. https:\/\/doi.org\/10.1038\/s41408-022-00624-6.","journal-title":"Blood Cancer J"},{"key":"1518_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1515\/cclm-2020-0581","volume":"59","author":"M Kohlhagen","year":"2020","unstructured":"Kohlhagen M, Dasari S, Willrich M, Hetrick M, Netzel B, Dispenzieri A, et al. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. Clin Chem Lab Med. 2020;59:155\u201363. https:\/\/doi.org\/10.1515\/cclm-2020-0581.","journal-title":"Clin Chem Lab Med"},{"key":"1518_CR21","doi-asserted-by":"crossref","unstructured":"Korn EL, Graubard BI analysis of health survey. New York, NY: Wiley; 1999.","DOI":"10.1002\/9781118032619"},{"key":"1518_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/sim.4780080504","volume":"8","author":"S Durrleman","year":"1989","unstructured":"Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551\u201361.","journal-title":"Stat Med"},{"key":"1518_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2105\/AJPH.90.8.1277","volume":"90","author":"D Baris","year":"2000","unstructured":"Baris D, Brown LM, Silverman DT, Hayes R, Hoover RN, Swanson GM, et al. Socioeconomic status and multiple myeloma among US blacks and whites. Am J Public Health. 2000;90:1277\u201381.","journal-title":"Am J Public Health"},{"key":"1518_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ijc.2910430404","volume":"43","author":"P Boffetta","year":"1989","unstructured":"Boffetta P, Stellman SD, Garfinkel L. A case-control study of multiple myeloma nested in the American Cancer Society prospective study. Int J Cancer. 1989;43:554\u20139.","journal-title":"Int J Cancer"},{"key":"1518_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00001648-199601000-00002","volume":"7","author":"SL Koessel","year":"1996","unstructured":"Koessel SL, Theis MK, Vaughan TL, Koepsell TD, Weiss NS, Greenberg RS, et al. Socioeconomic status and the incidence of multiple myeloma. Epidemiology. 1996;7:4\u20138.","journal-title":"Epidemiology"},{"key":"1518_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/01.ede.0000172135.61188.2d","volume":"16","author":"CK Blair","year":"2005","unstructured":"Blair CK, Cerhan JR, Folsom AR, Ross JA. Anthropometric characteristics and risk of multiple myeloma. Epidemiology. 2005;16:691\u20134.","journal-title":"Epidemiology"},{"key":"1518_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","volume":"371","author":"AG Renehan","year":"2008","unstructured":"Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(08)60269-X.","journal-title":"Lancet"},{"key":"1518_CR28","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3324\/haematol.13078","volume":"93","author":"JA Britton","year":"2008","unstructured":"Britton JA, Khan AE, Rohrmann S, Becker N, Linseisen J, Nieters A, et al. Anthropometric characteristics and non-Hodgkin\u2019s lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica. 2008;93:1666\u201377. https:\/\/doi.org\/10.3324\/haematol.13078.","journal-title":"Haematologica"},{"key":"1518_CR29","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","volume":"9","author":"H El-Khoury","year":"2022","unstructured":"El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022;9:e340\u20139. https:\/\/doi.org\/10.1016\/S2352-3026(22)00069-2.","journal-title":"Lancet Haematol"},{"key":"1518_CR30","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0025-6196(11)61090-2","volume":"82","author":"M Iwanaga","year":"2007","unstructured":"Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc. 2007;82:1474\u20139. https:\/\/doi.org\/10.1016\/S0025-6196(11)61090-2.","journal-title":"Mayo Clin Proc"},{"key":"1518_CR31","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/ajh.22095","volume":"86","author":"HK Park","year":"2011","unstructured":"Park HK, Lee KR, Kim YJ, Cho HI, Eun Kim J, Woong Kim K, et al. Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population. Am J Hematol. 2011;86:752\u20135. https:\/\/doi.org\/10.1002\/ajh.22095.","journal-title":"Am J Hematol"},{"key":"1518_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00277-011-1293-1","volume":"91","author":"L Eisele","year":"2012","unstructured":"Eisele L, Durig J, Huttmann A, Duhrsen U, Assert R, Bokhof B, et al. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol. 2012;91:243\u20138. https:\/\/doi.org\/10.1007\/s00277-011-1293-1.","journal-title":"Ann Hematol"},{"key":"1518_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00480-w","volume":"11","author":"S Rognvaldsson","year":"2021","unstructured":"Rognvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Oskarsson J, Petursdottir I, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:94. https:\/\/doi.org\/10.1038\/s41408-021-00480-w.","journal-title":"Blood Cancer J"},{"key":"1518_CR34","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/bloodadvances.2021006201","volume":"6","author":"CM Vachon","year":"2022","unstructured":"Vachon CM, Murray J, Allmer C, Larson D, Norman AD, Sinnwell JP, et al. Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method. Blood Adv. 2022;6:3746\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2021006201.","journal-title":"Blood Adv"},{"key":"1518_CR35","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1373\/jalm.2018.028902","volume":"4","author":"DL Murray","year":"2019","unstructured":"Murray DL, Willrich MAV. Evolution of myeloma testing in clinical chemistry with mass spectrometry. J Appl Lab Med. 2019;4:474\u20136. https:\/\/doi.org\/10.1373\/jalm.2018.028902.","journal-title":"J Appl Lab Med"},{"key":"1518_CR36","first-page":"626","volume":"89","author":"MA Thompson","year":"2004","unstructured":"Thompson MA, Kyle RA, Melton LJ 3rd, Plevak MF, Rajkumar SV. Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study. Haematologica. 2004;89:626\u20138.","journal-title":"Haematologica"},{"key":"1518_CR37","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00277-019-03825-5","volume":"98","author":"B Schmidt","year":"2019","unstructured":"Schmidt B, Debold E, Frank M, Arendt M, Dragano N, Durig J, et al. Socioeconomic position is positively associated with monoclonal gammopathy of undetermined significance in a population-based cohort study. Ann Hematol. 2019;98:2761\u20137. https:\/\/doi.org\/10.1007\/s00277-019-03825-5.","journal-title":"Ann Hematol"},{"key":"1518_CR38","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.3324\/haematol.2023.283191","volume":"108","author":"AY Sigurbergsdottir","year":"2023","unstructured":"Sigurbergsdottir AY, Rognvaldsson S, Thorsteinsdottir S, Sverrisdottir I, Sigurethardottir GA, Vietharsson B, et al. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study. Haematologica. 2023;108:3392\u20138. https:\/\/doi.org\/10.3324\/haematol.2023.283191.","journal-title":"Haematologica"},{"key":"1518_CR39","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/bloodadvances.2023010843","volume":"8","author":"DJ Lee","year":"2024","unstructured":"Lee DJ, El-Khoury H, Tramontano AC, Alberge JB, Perry J, Davis MI, et al. Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population. Blood Adv. 2024;8:1737\u201346. https:\/\/doi.org\/10.1182\/bloodadvances.2023010843.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01518-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:25:25Z","timestamp":1782199525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01518-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01518-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We confirm that all methods were performed in accordance with the relevant guidelines and regulations. Patients originally consented to participation in the NHANES study which covers the use of samples in the current study (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"100"}}